A randomised, double‐blinded, placebo‐controlled study on the efficacy of a unique extract of green‐lipped mussel (<i>Perna canaliculus</i>) in horses with chronic fetlock lameness attributed to osteoarthritis

Cayzer, J.; Hedderley, Duncan; Gray, Sir Muir

doi:10.1111/j.2042-3306.2011.00455.x

Cited by 19 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo equine studies on nutraceuticals are usually clinical trials 13, 34, 35, which are subject to an inherent lack of standardisation. This is highlighted by the low‐quality appraisal of most nutraceutical studies, using the score list described by Pearson and Lindinger 4.…”

Section: Discussionmentioning

confidence: 99%

The preventive effects of two nutraceuticals on experimentally induced acute synovitis

Water

Oosterlinck

Dumoulin

et al. 2016

Equine Veterinary Journal

View full text Add to dashboard Cite

SummaryBackgroundNutraceuticals are often used in the management of equine osteoarthritis, but scientific evidence of their efficacy is lacking.ObjectivesTo study the preventive effects of two new nutraceuticals after the experimental induction of synovitis in comparison with positive and negative control treatments.Study designBlinded, controlled, randomised experiment.MethodsTwenty‐four healthy Standardbred horses were randomly allocated to supplement AT (multi‐ingredient, 28 days), supplement HP (collagen hydrolysate, 60 days), meloxicam (4 days) or placebo (60 days). Synovitis was induced in the right intercarpal joint by intra‐articular injection of 0.5 ng lipopolysaccharide (LPS) of Escherichia coli while treatments were continued. Blood and synovial fluid were sampled before treatment, immediately prior to LPS injection, and at 8, 24 and 48 h post‐injection. Synovial fluid samples were analysed for total nucleated cell count (TNCC), total protein (TP) and selected biomarkers (prostaglandin E2 [PGE 2], interleukin‐6 [IL‐6], glycosaminoglycans [GAGs], type II collagen synthesis [CPII], matrix metalloproteinase [MMP]). Lameness was scored by visual examination and pressure plate analysis immediately prior to LPS injection, and at 8, 24 and 48 h post‐injection. Clinical examinations were performed before treatment, immediately prior to LPS injection, at 2, 4 and 6 h post‐injection, and then twice per day during the test period.ResultsBefore treatment and intra‐articular challenge, there were no statistically significant differences among the treatment groups for any of the parameters. After intra‐articular challenge, the placebo group showed significantly higher synovial fluid TP, TNCC and PGE 2 compared with the meloxicam group, although the model did not induce a relevant amount of lameness. Both nutraceuticals resulted in significantly lower synovial fluid TP, TNCC and PGE 2 compared with placebo. No statistical differences in IL‐6, GAGs, CPII or MMPs were observed among treatment groups. No adverse effects were observed.Main limitationsDespite evidence of synovitis, lameness was too mild to detect.ConclusionsThe preventive administration of these nutraceuticals showed anti‐inflammatory effects in this validated synovitis model. Therefore, further studies of their clinical applicability are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

The preventive effects of two nutraceuticals on experimentally induced acute synovitis

Water

Oosterlinck

Dumoulin

et al. 2016

Equine Veterinary Journal

View full text Add to dashboard Cite

show abstract

“…Evaluating treatments in clinical equine cases has the same challenges as human OA and only recently have there been any reasonable quality randomised control trials investigating the efficacy of articular therapeutics. 71-74 Again these studies were associated with identifying SMOAD effects rather than any disease-modifying activity of the drug. The problems associated with performing high-quality randomised, controlled studies and the lack of well-validated outcome measures determining disease-modifying activity in vivo make the use of equine experimental studies appropriate.…”

Section: Evaluation Of Treatments For Oamentioning

confidence: 99%

The horse as a model of naturally occurring osteoarthritis

McIlwraith

Frisbie

Kawcak

2012

Bone & Joint Research

244

262

View full text Add to dashboard Cite

Osteoarthritis (OA) is an important cause of pain, disability and economic loss in humans, and is similarly important in the horse. Recent knowledge on post-traumatic OA has suggested opportunities for early intervention, but it is difficult to identify the appropriate time of these interventions. The horse provides two useful mechanisms to answer these questions: 1) extensive experience with clinical OA in horses; and 2) use of a consistently predictable model of OA that can help study early pathobiological events, define targets for therapeutic intervention and then test these putative therapies. This paper summarises the syndromes of clinical OA in horses including pathogenesis, diagnosis and treatment, and details controlled studies of various treatment options using an equine model of clinical OA.

show abstract

“…Nevertheless, several medications are used intra-articularly, such as COs, hyaluronic acid (HA)/sodium hyaluronate (SH)/hyaluronate (HA), polysulfated glycosaminoglycans, sodium pentosan polysulfate, sodium chondroitin sulfate, somatostatin, N-acetyl- D-glucosamine, radiation synovectomy, dextrose prolotherapy, keratan sulfate orgotein, saline for washout, silicone, mucopolysaccharide polysulfuric acid ester, chloroquine, lactic acid solution, amikacin, gentamicin morphine, autologous serum, platelet-rich plasma, mesenchymal stem cells derived from bone marrow or adipose stromal vascular fraction, gene therapy using IL-1 antagonists, and ethanol. In addition, studies have used a topical liposomal formulation that contains diclofenac, lyophilized products from green-lipped mussel, extracorporeal shockwave, acupuncture, magnetic field, transcutaneous electrical nerve stimulation, therapeutic ultrasound, laser therapy, manual therapy, aquatic physical therapy and nutraceuticals food suplement (Uthman et al 2003;Caron 2005;Revenaugh 2005;Carmona et al 2007;Frisbie et al 2009;Goodrich and Nixon 2006;Santos et al 2009;Lindegaard et al 2010;Cayzer et al 2011;Kawcak et al 2011;Baccarin et al, 2012;McIIwraith et al 2011McIIwraith et al , 2012aCarmalt et al 2012;Lamas et al 2012;Vanderweerd et al 2012;Frisbie et al 2013;King et al 2013;Neuman et al 2013;Ferris et al 2014;Koenig et al 2014, de Grawn et al 2016. The use of controlled physical activity, as a complementary treatment, possibly improves the comfort level of the horse and decreases the inflammatory process (Kerbyson et al 2013).…”

Section: Possible Treatmentsmentioning

confidence: 99%

Osteoarthritis in horses - Part 2: a review of the intra-articular use of corticosteroids as a method of treatment

Souza

2016

Braz. arch. biol. technol.

View full text Add to dashboard Cite

show abstract

A randomised, double‐blinded, placebo‐controlled study on the efficacy of a unique extract of green‐lipped mussel (Perna canaliculus) in horses with chronic fetlock lameness attributed to osteoarthritis

Abstract: The LPPC significantly alleviated the severity of lameness and joint pain and improved response to joint flexion in horses with lameness attributable to OA in the fetlock.

Cited by 19 publications

References 20 publications

The preventive effects of two nutraceuticals on experimentally induced acute synovitis

The preventive effects of two nutraceuticals on experimentally induced acute synovitis

The horse as a model of naturally occurring osteoarthritis

Osteoarthritis in horses - Part 2: a review of the intra-articular use of corticosteroids as a method of treatment

Contact Info

Product

Resources

About